Nonclassical aspects of differential vitamin D receptor activation: Implications for survival in patients with chronic kidney disease

Drugs

Volumn 67, Issue 14, 2007, Pages 1999-2012

  Andress, Dennis ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Calcitriol receptor agonists, therapeutic use; Hyperparathyroidism, treatment; Kidney disorders; Paricalcitol, therapeutic use

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; CALCITRIOL; DOXERCALCIFEROL; PARICALCITOL; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR ACTIVATOR;

ANTIINFLAMMATORY ACTIVITY; BLOOD VESSEL CALCIFICATION; CALCIUM ABSORPTION; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; GENE EXPRESSION; HEART INFARCTION; HEART PROTECTION; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; KIDNEY DISEASE; MINERAL METABOLISM; MORBIDITY; MORTALITY; NONHUMAN; PARATHYROID GLAND; PROTEINURIA; RENAL PROTECTION; REVIEW; SMOOTH MUSCLE FIBER; STROKE; SURVIVAL; VASCULAR SMOOTH MUSCLE;

EID: 34948882837     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767140-00003     Document Type: Review

References (105)

1. Anavekar NS, McMurray JJV, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-95
2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305
3. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999; 56 Suppl. 73: S14-9
4. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-8
5. Rix M, Andreassen H, Eskildsen P, et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999; 56: 1084-93
6. Martinez I, Saracho R, Montenegro J, et al. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11 Suppl. 3: 22-8
7. Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006; 116: 2062-72
8. 3 in the parathyroid in vivo. J Clin Invest 1990; 86: 1968-75
9. Silver J, Russell J, Sherwood LM. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci 1985; 82: 4270-3
10. Indridason OS, Quarles LD, for the Durham Renal Osteodystrophy Study Group. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int 2000; 57: 282-92
11. Levine BS, Song M. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 1996; 7: 488-96
12. Andress DL. Vitamin D treatment in chronic kidney disease. Semin Dial 2005; 18: 315-21
13. Hudson JQ. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies. Ann Pharmacother 2006; 40: 1584-93
14. Brancaccio D, Bommer J, Coyne D. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies. Drugs 2007; 67 (14): 1981-98
15. Wu-Wong JR, Nakane M, Traylor L, et al. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs. Curr Opin Invest Drug 2005; 6: 245-54
16. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-28
17. Issa LL, Leong GM, Sutherland RL, et al. Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. J Bone Miner Res 2002; 17: 879-90
18. Takeyama K-I, Masuhiro Y, Fuse H, et al. Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol 1999; 19: 1049-55
19. Wu-Wong JR, Nakane M, Ma J, et al. Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 2006; 186: 20-8
20. 2 on calcium and phosphorus in normal and uremic rats. Kidney Int 2002; 62: 1277-84
21. 2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis 1998; 32 Suppl. 2: S40-7
22. Nakane M, Ma J, Rose AE, et al. Differential effects of vitamin D analogs on calcium transport. J Steroid Biochem Mol Biol 2007; 103: 84-9
23. Hirata M, Endo K, Katsumata K, et al. A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action. Nephrol Dial Transplant 2002; 17 Suppl. 10: 41-5
24. Hirata M, Katsumata K, Endo K, et al. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrol Dial Transplant 2003 Sep; 18 (9): 1770-6
25. Akizawa T, Suzuki M, Akiba T, et al. Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathy-roidism in haemodialysis patients: one-year administration study. Nephrol Dial Transplant 2002; 17 Suppl. 10: 28-36
26. Tamura S, Ueki K, Mashimo K, et al. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients. Clin Exp Nephrol 2005 Sep; 9 (3): 238-43
27. Martin KJ, Gonzalez EA. Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis 2001; 38 Suppl. 5: S34-40
28. Goltzman D. Use of genetically modified mice to examine skeletal anabolic activity of vitamin D. J Steroid Biochem Mol Biol 2007; 103: 587-91
29. Nakane M, Fey TA, Dixon DB, et al. Differential effects of vitamin D analogs on bone formation and resorption. J Steroid Biochem Mol Biol 2006; 98: 72-7
30. Hirata M, Katsumata K, Masaki T, et al. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int 1999 Dec; 56 (6): 2040-7
31. Joist HE, Ahya SN, Giles K, et al. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. Clin Nephrol 2006; 2006: 335-41
32. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-25
33. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-80
34. Young EW, Albert JM, Akiba T, et al. Vitamin D therapy and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS) [abstract]. J Am Soc Nephrol 2005; 16: 278A
35. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003 Jul 31; 349 (5): 446-56
36. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006 Nov; 70 (10): 1858-65
37. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. Epub 2007 Aug 8
38. USRDS. United States Renal Data System. USRDS 2006 Annual Data Report, 2006 [online]. Available from URL: http://www.usrds.org/adr.htm [Accessed 2007 Sep 6]
39. Rivard A, Andres V. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases. Histol Histopathol 2000; 15: 557-71
40. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701
41. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-40
42. Yildiz A, Memisoglu E, Oflaz H, et al. Atherosclerosis and vascular calcification are independent predictors of left ven-tricular hypertrophy in chronic haemodialysis patients. Nephrol Dial Transplant 2005; 20: 760-7
43. Wilson PWF, Kauppila LI, O'Donnell C, et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001; 103: 1529-34
44. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-42
45. Zimmerman J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-58
46. London GM, Geurin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-20
47. Chen NX, Duan D, O'Neill KD, et al. The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney Int 2006; 70: 1046-53
48. Chen NX, O'Neill KD, Duan D, et al. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002; 62: 1724-31
49. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: 10-7
50. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2005; 69: 33-43
51. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-64
52. 3 modulates growth of vascular smooth muscle cells. J Clin Invest 1991; 87: 1889-95
53. 3: studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 1989; 83: 1903-15
54. Cardus A, Gallego C, Muray S, et al. Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells [in Spanish]. Nefrologia 2003; 23 Suppl. 2: 117-21
55. Cardus A, Parisi E, Gallego C, et al. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 2006; 69: 1377-84
56. Wu-Wong JR, Noonan W, Ma J, et al. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther 2006; 318: 90-8
57. Cardus A, Panizo S, Parisi E, et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: 860-6
58. Wanner C, Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002; 17 Suppl. 8: 29-32
59. Timms PM, Mannan N, Hitman GA, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders. Q J Med 2002; 95: 787-96
60. Jung HH, Kim S-W, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant 2006; 21: 1915-20
61. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-54
62. Watson KE, Parhami F, Shin V, et al. Fibronectin and collagen I matrixes promote calcification of vascular cells in vitro, whereas collagen IV matrix is inhibitory. Arterioscler Thromb Vasc Biol 1998; 18: 1964-71
63. Parhami F, Basseri B, Hwang J, et al. High-density lipoprotein regulates calcification of vascular cells. Circ Res 2002; 91: 570-6
64. Tintut Y, Patel J, Parhami F, et al. Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000; 102: 2636-42
65. Watson KE, Bostrom K, Ravindranath R, et al. TGF-β1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest 1994; 93: 2106-13
66. Böstrom K, Watson KE, Horn S, et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993; 91: 1800-9
67. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81
68. Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix gla protein-deficient mice: evidence for osteopontin as an induci-ble inhibitor of vascular calcification in vivo. J Exp Med 2002; 196: 1047-55
69. 3. Cell Tissue Res 1999; 297: 249-59
70. 3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 2002; 274: 323-33
71. Panichi V, De Pietro S, Andreini B, et al. Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int 1998; 54: 1463-9
72. Türk S, Akbulut M, Yildiz A, et al. Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density. Nephron 2002; 90: 188-94
73. Virdi AS, Cook LJ, Oreffo RO, et al. Modulation of bone morphogenetic protein-2 and bone morphogenetic protein-4 gene expression in osteoblastic lines. Cell Mol Biol 1998; 44: 1237-46
74. Abe H, Iehara N, Utsunomiya K, et al. A vitamin D analog regulates mesangial cell smooth muscle phenotypes in a transforming growth factor-β type II receptor-mediated manner. J Biol Chem 1999; 274: 20874-8
75. 3 stimulates the synthesis of matrix γ-carboxyglutamic acid protein by osteosarcoma cells: mutually exclusive expression of vitamin K-dependent bone proteins by clonal osteoblastic cell lines. J Biol Chem 1988; 263: 911-6
76. Mizobuchi M, Finch JL, Martin DR, et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. Epub 2007 Jun 27
77. Ohsawa M, Koyama T, Yamamoto K, et al. 1α,25-Dihydroxyvitamin D3 and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation 2000; 102: 2867-72
78. Aihara K, Azuma H, Akaike M, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 2004; 279: 35798-802
79. Petrie MS, Harrell TE, Schwartz GG, et al. Production of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells: differential responses to calcitriol and paricalcitol. J Thromb Haemost 2004; 2: 2266-7
80. Nordt TK, Peter K, Ruef J, et al. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost 1999; 82 Suppl.: 14-8
81. Nitta K, Akiba T, Uchida K, et al. Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res 2004; 27: 47-52
82. Patrianakos AP, Parthenakis FI, Karakitsos D, et al. Relation of proximal aorta stiffness to left ventricular diastolic function in patients with end-stage renal disease. J Am Soc Echocardiogr 2007; 20: 314-23
83. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 103: 987-92
84. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12: 2759-67
85. Noonan W, Ma J, Dixon D, et al. Differential effects of vitamin D analogs on aortic calcification and pulse wave velocity in uremic rats [abstract no. SP355]. XLIII European Renal Association-European Dialysis and Transplant Association (ERAEDTA) Congress; 2006 Jul 15-18; Glasgow
86. Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005 Sep; 16 (9): 2778-88
87. Thadhani RAJ, Achinger S, Shivalingappa V, et al. Paricalcitol and cardiac structure and function in animals and humans [abstract no. TH-FC155]. J Am Soc Nephrol 2006; 17: 21A
88. Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-38
89. Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of systemic and cardiac reninangiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: 125-32
90. Wu-Wong JR, Nakane M, Ruan X, et al. The role of vitamin D receptor in regulating renin [abstract no. SO35]. XLIII European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress; 2005 Jun 4-7; Istanbul
91. Nakane M, Fey TA, Droz BA, et al. Effect of paricalcitol on renal renin mRNA expression in vitamin D-deficient rats [abstract no. TH-PO288]. American Society of Nephrology (ASN) 38th Renal Week Meeting; 2005 Nov 8-13; Philadelphia (PA)
92. Pan L, Black TA, Shi Q, et al. Critical roles of a cyclic AMP responsive element and an E-box in regulation of mouse renin gene expression. J Biol Chem 2001; 276: 45530-8
93. Tian J, Liu Y, Williams LA, et al. Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant 2007; 22: 321-8
94. 3 on compensatory renal growth in the growing rat. Kidney Int 1991; 40: 212-8
95. Weih M, Orth S, Weinreich T, et al. Inhibition of growth by calcitriol in a proximal tubular cell line (OK). Nephrol Dial Transplant 1994; 9: 1390-4
96. 3 on human mesangial cells. Am J Kidney Dis 1991; 18: 359-66
97. 3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998; 53: 1696-705
98. Tan X, Li YC, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006; 17: 3382-93
99. Sanai T, Tokumoto M, Hirano T, et al. Different effects of 22-oxacalcitriol and calcitriol on the course of experimental chronic renal failure. J Lab Clin Med 2002; 140: 242-9
100. Keane WF, Eknoyan G, for the National Kidney Foundation PARADE Committee. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33: 1001-10
101. Foley RN, Parfrey PS, Harnett JD, et al. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 1996; 7: 728-36
102. De Zeeuw D, Remuzzi G, Parving H-H, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-20
103. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-8
104. Maenpaa PH, Vaisanen S, Jaaskelainen T, et al. Vitamin D(3) analogs (MC 1288, KH 1060, EB 1089, GS 1558, and CB 1093): studies on their mechanism of action. Steroids 2001; 66 (3-5): 23-5
105. Imanishi Y, Inaba M, Seki H, et al. Increased biological potency of hexaflourinated analogs of 1,25-dihydroxyvitamin D3 on bovine parathyroid cells. J Steroid Biochem Mol Biol 1999; 70 (4): 243-8